Last updated on August 2019

A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Macular Degeneration
  • Age: Between 50 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

• Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal.

• Vaccination against Neisseria meningitidis and Streptococcus pneumoniae received at least 2 weeks prior to first dose of investigational product

• Well-demarcated geographic atrophy (GA) due to AMD

• Best-corrected visual acuity (BCVA) letter score of 35 letters (approx. 20/200 Snellen equivalent) or better on the ETDRS chart

• Must have clear ocular media and adequate pupillary dilation in the study eye to permit high-quality fundus imaging

Exclusion Criteria:

• Clinically-significant abnormalities in medical history

• A lack of full recovery from any infection for at least 14 days prior to the Study Drug administration

• Chronic treatment with steroids, including topically or intravitreally administered

• History or presence of diabetic retinopathy or diabetic macular edema (DME)

• History or presence of a disease other than AMD that could affect vision or safety assessments

• Prior treatment with another investigational drug, biological agent, or device

• Other protocol-specified inclusion/exclusion criteria may apply

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.